Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study

Kuniko Sunami1 | Hitoshi Ichikawa2,3 | Takashi Kubo1,2,3 | Mamoru Kato4 | Yutaka Fujiwara5 | Akihiko Shimomura5 | Takafumi Koyama5 | Hiroki Kakishima1 | Mayuko Kitami1 | Hiromichi Matsushita1 | Eisaku Furukawa4 | Daichi Narushima4 | Momoko Nagai4 | Hirokazu Taniguchi1 | Noriko Moto1 | Shigeki Sekine1 | Akiko Maeshima1 | Taisuke Mori1 | Reiko Watanabe1 | Masayuki Yoshida1 | Akihiko Yoshida1 | Hiroshi Yoshida1 | Kaishi Satomi1 | Aoi Sukseda1 | Taiki Hashimoto1 | Toshio Shimizu5 | Satoru Iwasa5 | Kan Yonemori5 | Ken Kato6 | Chigusa Morizane7 | Chitose Ogawa8 | Noriko Tanabe9 | Kokichi Sugano9,10 | Nobuyoshi Hiraoka1 | Kenji Tamura11 | Teruhiko Yoshida9 | Yasuhiro Fujiwara11,12 | Atsushi Ochiai13 | Noboru Yamamoto5 | Takashi Kohno3,14

1Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
2Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan
3Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan
4Department of Bioinformatics, National Cancer Center Research Institute, Tokyo, Japan
5Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
6Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
7Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
8Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
9Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan
10Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Tochigi, Japan
11Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
12Strategic Planning Bureau, National Cancer Center, Tokyo, Japan
13Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan
14Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan

Correspondence
Takashi Kohno, Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.
Email: tkkohno@ncc.go.jp

Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a hospital-based prospective study (TOP-GEAR project, 2nd stage) to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes (the NCC Oncopanel test). We examined 230 cases (comprising more than 30 tumor types) of advanced solid tumors, all of which were matched with nontumor samples. Gene profiling data...
1 | INTRODUCTION

In a clinical setting, massively parallel next-generation sequencing (NGS) has enabled simultaneous examination of more than 100 genes to detect “actionable” mutations that help oncologists with respect to diagnosis and selection of potential treatment regimens involving molecular-targeted drugs.\(^1,2\) Such systems are referred to as “tumor-profiling multiplex gene panel tests” or more simply “gene panel tests.” Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories in the USA have implemented a variety of NGS-based gene panel tests. For example, scientists at the Memorial Sloan Kettering Cancer Center implemented the MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) test to examine 348 genes and reported that 37% of 10,000 investigated patients harbored at least 1 actionable mutation and that 11% of the first 5009 patients who received an MSK-IMPACT test were subsequently enrolled in genomically matched clinical trials.\(^3\) Foundation Medicine (Cambridge, MA, USA) developed the FoundationOne CDx test to examine 324 genes and the tumor mutational burden (TMB),\(^4\) which is an emerging biomarker of sensitivity to immune checkpoint blockade therapy.\(^5,6\) These 2 tests have now been approved by the FDA, further facilitating cancer genome medicine in the USA by promoting insurance reimbursement.\(^7\)

Gene panel tests have not yet been implemented in routine oncological practice in Japan; ie, they have not been reimbursed by the national insurance system run by the Japanese Ministry of Health, Labor, and Welfare (MHLW).\(^8\) However, several academic institutions have examined the feasibility and utility of gene panel tests,\(^1,2\) and 3 major Japanese cancer-related societies (the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association) have issued consensus clinical practice guidelines for NGS-based cancer tests (the Consensus Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment [Edition 1.0]);\(^9\) http://www.j smo.or.jp/about/kanko.html#guideline. Therefore, it is likely that implementation of gene panel tests in Japan will happen soon.

We have been undertaking a prospective hospital-based cohort study to investigate the feasibility and utility of NGS-based analysis of 114 cancer-associated genes using the National Cancer Center (NCC) Oncopanel test (Table 1). Many different cases of advanced solid tumors were analyzed at a quality-assured laboratory at the NCC Hospital (NCCH; Tokyo, Japan). Detected gene aberrations and their annotations were reported to the treating physicians. This study formed the second stage of the TOP-GEAR project (Trial of Onco-Panel for Gene-profiling to Estimate both Adverse events and Response during cancer treatment; UMIN 000011141). This follows the first\(^10\) stage in which tumor samples were analyzed at the NCC Research Institute.

Here, we summarize the results of the first 230 cases analyzed during the second stage of TOP-GEAR. The results indicate the feasibility and utility of the gene panel test in a clinical oncology setting. From April 2018, the NCC Oncopanel test is being tested by 50 Core and Liaison Hospitals for Cancer Genomic Medicine in Japan (within the Advanced Medical Care B system) to validate its feasibility and utility.\(^11\)

2 | PATIENTS AND METHODS

2.1 | Patient population

Patients aged 16 years or older, diagnosed histopathologically with a solid tumor, and who would finish or had finished standard chemotherapy were enrolled in the TOP-GEAR study (n = 248). Next, the availability of archival formalin-fixed paraffin-embedded (FFPE) tumor tissues with tumor cell content 10% or higher was checked for each case (pathologists estimated tumor cell content by counting the nuclei of tumor and nontumor cells within each tissue); appropriate cases were analyzed in the study to address the feasibility and utility of the NCC Oncopanel test (n = 230). The study was approved by the NCC Institutional Review Board, and all patients provided written informed consent for the use of genomic and clinical data for research purposes. When consent was obtained, patients were also asked whether they will be reported for the results of somatic and germline gene alteration, respectively, from treating physicians. Among the 230 analyzed cases, 228 (99.1%) and 219 cases (95.2%) gave consent to receive results of somatic and germline tests, respectively; therefore, results were returned to patients accordingly.
2.2 | Next-generation sequencing-based multiplex gene assay (NCC Oncopanel test)

The NCC Oncopanel test is a hybridization capture-based NGS assay designed to examine mutations, amplifications, and homozygous deletions of the entire coding region of 114 genes of clinical or preclinical relevance, along with rearrangements of 12 oncogenes included in the panel (Table 1). For the analysis, 5 10-μm sections or 10 4-5-μm sections were prepared from FFPE tumor tissues. Peripheral blood (5 mL) collected from the same patients was used as a control to allow discrimination of somatic and germline mutations. Genomic DNA was extracted from tumor tissues and peripheral blood cells using a QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany) and a Maxwell RSC Blood DNA kit (Promega, Fitchburg, WI, USA), respectively. The extracted DNA was quantified using a Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) and a Qubit 3.0 Fluorometer (Thermo Fisher Scientific). Quantitative PCR analysis of the \textit{RPPH1} (RNase P) locus was carried out, and the ratio of PCR-amplifiable DNA to total double-stranded DNA was used to indicate DNA quality. When this value (Q-value) was greater than or equal to 0.1, the DNA was sent for sequencing.\textsuperscript{10} The Q-value reflects the fraction of PCR-active DNA molecules in each sample. Our previous clinical sequencing study\textsuperscript{10} verified empirically that, in the cases with high-quality DNA, it is possible to reduce the amount of input DNA to 50 ng. However, in cases with poor-quality DNA, use of large amounts of DNA (more than 800 ng) did not efficiently improve the results; this was likely due to saturation of the DNA capture-based system. Therefore, the threshold for DNA quantity was set according to DNA quality: the threshold was 50 ng or more for samples with a Q-value less than or equal to 0.8; 100 ng or more for samples with a Q-value greater than or equal to 0.4 and less than 0.8; 200 ng or more for samples with a Q-value greater than or equal to 0.2 and less than 0.4; and 400 ng or more for samples with a Q-value greater than or equal to 0.1 and less than 0.2. Sequencing libraries were prepared from 50-800 ng DNA (depending on the Q-value) using the SureSelect XT reagent (Agilent Technologies, Santa Clara, CA, USA) and a KAPA Hyper Prep kit (KAPA Biosystems, Wilmington, MA, USA) and then analyzed on the Illumina MiSeq.

| Mutations and copy number alterations for all exons | Fusions |
|-----------------------------------------------------|---------|
| ABL1 | CRKL | IDH2 | NF1 | RAC2 | ALK |
| ACTN4 | CREBBP | IGF1R | NFE2L2/Nrf2 | RAD51C | AKT2 |
| AKT1 | CTNNB1 | IGF2 | NOTCH1 | RAF1/CRAF | BRAF |
| AKT2 | CUL3 | IL7R | NOTCH2 | RB1 | ERBB4 |
| AKT3 | DDR2 | JAK1 | NOTCH3 | RET | FGFR2 |
| ALK | EGF | JAK2 | NRAS | RHOA | FGFR3 |
| APC | ENO1 | JAK3 | NRG1 | ROS1 | NRG1 |
| ARAF | EP300 | KDM6A/UTX | NTRK1 | SETBP1 | NTRK1 |
| ARID1A | ERBB2/HER2 | KEAP1 | NTRK2 | SETD2 | NTRK2 |
| ARID2 | ERBB3 | KIT | NTRK3 | SMAD4 | PDGFRA |
| ATM | ERBB4 | KRAS | NT5C2 | SMARC4/BRG1 | RET |
| AXIN1 | ESR1/ER | MAP2K1/MEK1 | PALB2 | SMARC1 | ROS1 |
| AXL | EZH2 | MAP2K2/MEK2 | PBRM1 | SMO |
| BAP1 | FBXW7 | MAP2K4 | PDGFRA | STAT3 |
| BARD1 | FGFR1 | MAP3K1 | PDGFRB | STK11/LKB1 |
| BCL2L11/BIM | FGFR2 | MAP3K4 | PIK3CA | TP53 |
| BRAF | FGFR3 | MDM2 | PIK3R1 | TSC1 |
| BRCA1 | FGFR4 | MDM4 | PIK3R2 | VHL |
| BRCA2 | FLT3 | MET | POLD1 | |
| CCND1 | GNA11 | MLH1 | POLE | |
| CD274/PD-L1 | GNAQ | MTR | PRKCI | |
| CDK4 | GNAS | MSH2 | PTCH1 | |
| CDKN2A | HRAS | MYC | PTEN | |
| CHEK2 | IDH1 | MYCN | RAC1 | |

**TABLE 1** Genes examined by the NCC Oncopanel test (n = 114)
or NextSeq platform (Illumina, San Diego, CA, USA) with 150 bp paired-end reads.

### 2.3 Bioinformatics analysis

Mapping of NGS reads to the human reference genome was carried out using the Burrows-Wheeler Aligner and the Burrows-Wheeler Aligner-Smith-Waterman algorithm after removal of adapter sequences using a Cutadapt program. Thresholds for mean read depth of coverage for gene aberration calls were set according to tumor cell content, as defined by pathological examination; the threshold was 200 for samples with more than 50% cellularity, 250 for samples with 20%-50% cellularity, and 500 for samples with less than 20% cellularity. For samples with a mean read depth of coverage above these thresholds, somatic mutations (single nucleotide variants and short insertions and deletions (indels)), gene amplifications, homozygous deletions, and gene fusions were detected using the cisCall program. Mutations with 5% or more variant allele frequencies and amplifications with more than 4-fold copy number increases were defined as positive. Genes with less than 0.5-fold copy number decreases were considered as homozygous deletion candidates and judged by manual inspection using the Integrative Genomics Viewer (IGV). Data from the refGene (20150219), ensGene (20140406), and COSMIC (version 71) databases were used to annotate each gene aberration. The level of cross-individual contamination in tumor tissues was estimated by the ContEst program, as well as by manual inspection of single nucleotide polymorphism sites using IGV. Tumor samples thought to show cross-individual contamination were removed from the study.

Germline mutations in 13 genes responsible for hereditary cancers (APC, BRCA1, BRCA2, MLH1, MSH2, PTEN, RB1, RET, SMAD4, STK11, TP53, TSC1, and VHL), for which the American College of Medical Genetics and Genomics (ACMG) recommends reporting of incidental or secondary findings, were detected by the GATK program (version 3) using NGS data obtained from peripheral blood DNA. Single nucleotide polymorphisms were removed if they showed a threshold of 0.01 or more allele frequency in any of the following databases: 1000 Genomes (1 kgp, 201204) (http://www.w1000genomes.org); the NHLBI GO Exome Sequencing Project (ESP6500) (http://evs.gs.washington.edu/EVS/); the Human Genetic Variation Database (HGVD, 20131010) (http://www.genome.med.kyoto-u.ac.jp/SnpDB); and the Integrative Japanese Genome Variation Database (JIGVD, 20151218) (https://jigvd.megabank.tohoku.ac.jp/). All somatic and germline aberrations judged to be positive were validated by manual inspection on IGV.

### 2.4 Definition of actionable

Actionable gene aberrations for drug selection were those predicted to confer sensitivity/resistance to either an approved targeted agent or an experimental targeted agent currently in clinical trials. Evidence levels were added to each gene aberration according to Clinical Practice Guidance for Next Generation Sequencing in Cancer Diagnosis and Treatment (issued by the Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, and the Japanese Cancer Association). The guidance cites the following levels of evidence for each gene aberration: level 1A, a Pharmaceuticals and Medical Devices Agency (PMDA)-approved biomarker for the tumor type; 1B, an FDA-approved biomarker for the tumor type (not approved by the PMDA) or a biomarker verified by a prospective molecularly driven clinical trial; 2A, a biomarker identified by subgroup analysis in a prospective clinical trial; 2B, an approved biomarker for a different tumor type or a biomarker with evidence supporting its clinical utility; 3A, a biomarker with evidence of proof-of-concept in at least one case report; 3B, a biomarker with evidence obtained from in vitro/in vivo experiments; and 4, other gene mutations in cancer. In the present study, gene aberrations with evidence levels 1A-3A were judged as actionable for drug selection. Evidence levels 1A-3A correspond to evidence levels A-C listed in guidance documents published by the Association for Molecular Pathology, ACMG, the American Society of Clinical Oncology, and the College of American Pathologists.

In addition, actionable aberrations for diagnosis and prognosis were also considered according to Japanese guidelines. As for germline mutations in the above-mentioned 13 genes, truncating mutations and mutations deposited as "pathogenic" in the ClinVar database were judged as deleterious and, therefore, significant.

### 2.5 Tumor mutational burden

Tumor mutational burden was defined as the number of somatic, coding, base substitutions, and indel mutations per megabase of genome examined (ie, the total number of mutations divided by 1.38 Mb [the genome size of target regions covered by the NCC Oncopanel assay]). All base substitutions and indels in the coding region of targeted genes, including synonymous alterations, were counted. DNAs extracted from tumor and nontumor tissues of lung, breast, and ovarian cancers were measured previously by whole exome sequencing, and were subjected to NCC Oncopanel analysis to verify their utility for estimating TMB.

### 2.6 Molecular tumor board (expert panel)

Actionable gene aberrations and possible treatments were discussed at the molecular tumor board meeting by a multidisciplinary team at NCCH, called the "expert panel," which met twice per month. The board included medical oncologists, pediatric oncologists, pathologists, genome researchers, bioinformaticians, and genetic counselors. Board members discussed genetically informed treatment options and other issues such as authorization of pathological diagnoses and interpretation of somatic/germline variants. The report
was returned to the treating physicians, who explained the details to their patients.

3 | RESULTS

3.1 | Feasibility of testing

Between May 2016 and May 2017, 248 patients were enrolled in TOP-GEAR and the availability of appropriate tumor tissues was checked (Figure 1A, Table S1). Eighteen cases were excluded due to lack of sufficient tumor tissue sample (n = 16) or diagnosis of a benign tumor upon pathological re-review (n = 2). Thus, 230 cases were analyzed to test the feasibility and utility of the NCC Oncopanel test. The 230 cases comprised 140 surgical (60.9%) and 90 (39.1%) biopsy specimens (Figure 1A). Eighteen of these were removed due to low DNA yield (n = 8) or quality (n = 10), measured according to the criteria described above10 (Figure 1A). Therefore, 212 (92.2%) of the 230 cases were subjected to NGS analysis. After analysis, 9 (3.9%) cases were judged as having tissue cross-contamination. ContEst program analysis revealed that 2 of these had >5% tissue cross-contamination; the remaining 7 cases were inferred by IGV inspection (Figure S1). In addition, the mean read depth in another 16 (7.0%) cases was below the set thresholds. Thus, gene profiling data were obtained for 187 (88.2%) of 212 patients (success rate, 81.3%). In these samples, medians for the mean read depth and allele frequencies of detected mutations were 626 and 27.2%, respectively (Figure S2). The average turnaround time, defined as the interval between the date of sample arrival and the date of the molecular tumor board meeting, was 37 days (median, 32 days; range, 9-84 days).

The 187 cases comprised more than 30 types of tumor. The major tumor types are shown in Figure 1B and listed in Table S2. Sarcoma was the most common tumor type, accounting for 22.5% (n = 42) of cases, followed by non-small-cell lung cancer (n = 26, 13.9%), ovarian cancer (n = 12, 6.4%), and pancreatic cancer (n = 10, 5.3%). Notably, 97 cases (51.9%) were rare cancers (defined as those with an incidence rate of fewer than 6 per 100 000 persons per year) (Table S2).
3.2 Percentage of cases harboring actionable gene aberrations

At least 1 genetic aberration was detected in 156 of the 187 cases for which gene profiling data were obtained (83.4%) (Figure 2A, detailed data in Table S3). Frequently altered genes were TP53 (40.1%, 75/187), KRAS (15.5%, 29/187), PIK3CA (11.8%, 22/187), and APC (5.3%, 10/187). Notably, EGFR mutations were detected in 6 lung cancer cases that received companion diagnostics for EGFR mutations and 3 of them were judged to be negative. All of these EGFR mutations detected by the NCC Oncopanel test were rare variants not detected by existing companion diagnostics. The NCC Oncopanel test also detected an Asian-specific polymorphism in BCL2L11/BIM, which is thought to be associated with resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. The deletion allele conferring resistance was observed in 24 (12.8%) cases, which is consistent with the percentage in the Asian population.

According to evidence levels 1A-3A, 109 cases (58.2%) harbored at least 1 actionable gene aberration (Figure 2A). The 156 cases were ranked according to the strongest (maximum) evidence as follows: 14 (7.4%) cases harbored level 1A aberrations; 9 (4.8%) harbored level 1B aberrations; 9 (4.8%) harbored level 2A aberrations; 33 (17.6%) harbored level 2B aberrations; and 44 (23.5%) harbored level 3A aberrations. The other 47 cases harbored level 3B aberrations (n = 25; 13.3%) or level 4 aberrations (n = 22; 11.8%).

Next, we examined the percentage of cases with each tumor type (Figure 2B). When the 187 cases were categorized as carcinoma.
or sarcoma, we found that the percentage of carcinoma cases with actionable gene aberrations was greater than that of sarcoma cases (95/145, 65.5% vs 14/42, 33.3%, respectively). The difference was statistically significant ($P = 2.0 \times 10^{-4}$; $\chi^2$ test). In agreement with previous genome-wide sequencing studies, we frequently identified actionable aberrations (>80%) in cases of non-small-cell lung cancer, biliary cancer, and breast cancer.

### 3.3 Fraction of cases with a high TMB

To examine the ability of the NCC Oncopanel test to evaluate the TMB, we used the NCC Oncopanel test to examine 20 additional cancer cases in which the TMB had been measured in previous studies by whole exome sequencing. We then compared the TMB values generated by the 2 assays. The TMB values (the number of somatic mutations per megabase after subtracting germline variations detected in the corresponding peripheral blood DNA) generated by the NCC Oncopanel test showed a strong correlation ($R^2 = 0.98$) with those by whole exome sequencing, indicating that the NCC Oncopanel test is more appropriate than other gene panel tests as a tool for evaluating the TMB (Figure 3).

In particular, 8 cases with a TMB value of more than 20 mutations/Mb had endogenous or exogenous risk factors linked to a high TMB. Mismatch repair deficiency, an endogenous factor causing a high TMB, occurred in 2 of 8 cases that harbored loss of function mutations (a somatic P415 fs mutation and a germline Q341* mutation) in the MSH2 gene. Temozolomide, a mutagenic alkylate agent, was used to treat 1 case of glioma and the tumor sample obtained after treatment was subjected to the NCC Oncopanel test. The remaining 4 patients had been considered exposed to exogenous mutagenic factors (ie, UV light and cigarette smoke). A prospective clinical trial study showed that a high TMB phenotype (defined by 10 or more mutations/Mb) is a biomarker for responses to immune checkpoint blockade therapy; therefore, a high TMB was defined as evidence level 1B for drug selection. Among the 17 high TMB cases, 2 had been judged as negative for original actionable gene aberrations. Thus, taking high TMB into account meant that the fraction of cases with actionable gene aberrations was 59.4% (111/187).

Evidence levels 1A-3A in the Clinical Practice Guidelines for Next Generation Sequencing in Cancer Diagnosis and Treatment correspond to evidence levels A-C in the guidelines published by the Association for Molecular Pathology, ACMG, American Society of Clinical Oncology, and College of American Pathologists. Therefore, the same percentage (ie, 59.4%) of cases was also judged as positive for aberrations based on evidence levels A-C; ie, they had clinically significant gene aberrations.

### 3.4 Drug treatment according to actionable gene aberrations

Drug treatment according to actionable gene aberrations detected by the NCC Oncopanel test was examined as of May 31, 2018, ie, approximately 1 year after enrollment of the last case. In total, 25 (13.4%) cases received molecular-targeted drugs in accordance with their identified gene aberrations (Table 2). A number of cases (n = 19, 76.0%) received therapy with drugs that were not approved for their particular tumor. Among these, 15 (60.0%) received investigational drugs after enrollment into clinical trials matched to their gene aberrations, and the remaining 4 (16.0%) received kinase inhibitory drugs approved for treatment of different tumor types in Japan (ie, off-label use). The remaining 6 (24%) cases were prescribed PMDA-approved molecular-targeted drugs. By contrast, 86 cases with actionable gene aberrations (including a high TMB) did not receive genomically matched therapies. Among these, 9 cases were dead or had poor performance status at the time that the results were returned. For the majority of the remaining cases (n = 77), there were no available/accessible genomically matched clinical trials or drugs.

### 3.5 Diagnosis and prognosis based on actionable gene aberrations

The results of gene profiling using the NCC Oncopanel test were also used for diagnosis and prognosis. Germline mutations causing hereditary cancers were identified in 6/187 (3.2%) patients (Table 3). All were defined at evidence level 1 for diagnosis. The diagnoses were as follows: hereditary breast and ovarian cancer based on deleterious BRCA1 or BRCA2 mutations (n = 4), Lynch syndrome based on a deleterious MSH2 mutation (n = 1), and Li-Fraumeni syndrome based on a deleterious TP53 mutation (n = 1). Subsequently, 3 patients received genetic counseling from Genetic Medicine and Services at NCCH. Two
| No. | TOP-GEAR ID | Tumor type                          | Age (years) | Gender | AYA | Rare cancer         | Actionable gene aberration | Drug                | Drug type         |
|-----|------------|------------------------------------|-------------|--------|-----|---------------------|-----------------------------|------------------------|--------------------|
| 1   | 5022       | Ovarian cancer                      | 37          | F      | Y   | Y                   | KRAS mutation               | Pan-RAF inhibitor     | Investigational drug |
| 2   | 5025       | Colorectal cancer                   | 69          | M      | n   | n                   | KRAS mutation               | Pan-RAF inhibitor     | Investigational drug |
| 3   | 5010       | Colorectal cancer                   | 44          | M      | n   | n                   | BRAF mutation               | Pan-RAF inhibitor     | Investigational drug |
| 4   | 5058       | Pancreatic cancer                   | 47          | M      | n   | n                   | KRAS mutation               | Pan-RAF inhibitor     | Investigational drug |
| 5   | 5004       | Pancreatic cancer                   | 58          | F      | n   | n                   | KRAS mutation               | ERK inhibitor          | Investigational drug |
| 6   | 5054       | Esophageal carcinoma                | 61          | M      | n   | n                   | FGFR2 amplification         | FGFR2 inhibitor       | Investigational drug |
| 7   | 5017       | Soft tissue sarcoma (Malignant cardiac tumor) | 28          | F      | Y   | Y                   | MDM2 amplification         | HDM2 inhibitor        | Investigational drug |
| 8   | 5130       | Soft tissue sarcoma (Liposarcoma)   | 54          | F      | n   | Y                   | MDM2 amplification         | HDM2 inhibitor        | Investigational drug |
| 9   | 5076       | Non-small-cell lung cancer          | 67          | M      | n   | n                   | Tumor mutation burden high  | Immunocheckpoint inhibitor | Investigational drug |
| 10  | 5160       | Non-small-cell lung cancer          | 42          | M      | n   | n                   | Tumor mutation burden high  | Immunocheckpoint inhibitor | Investigational drug |
| 11  | 5078       | Non-small-cell lung cancer          | 67          | F      | n   | n                   | CCDC6-RET fusion           | Alectinib            | Investigational drug |
| 12  | 5164       | Breast cancer                       | 35          | F      | Y   | n                   | HER2 amplification          | HER2 ADC              | Investigational drug |
| 13  | 5215       | Biliary cancer                      | 68          | M      | n   | n                   | HER2 amplification          | HER2 ADC              | Investigational drug |
| 14  | 5227       | Tumors of unknown primary site      | 65          | F      | n   | Y                   | PIK3CA mutation             | TORC1/2 inhibitor     | Investigational drug |
| 15  | 5018       | Apocrine adenocarcinoma             | 70          | M      | n   | Y                   | FGFR2-CLIP1 fusion          | FGFR inhibitor        | Investigational drug |
| 16  | 5060       | Inflammatory myofibroblastic tumor  | 51          | M      | n   | Y                   | CLTC-ALK fusion            | Alectinib            | Off-label use       |
| 17  | 5219       | Mastocytoma                         | 39          | M      | Y   | Y                   | KIT mutation                | Imatinib              | Off-label use       |
| 18  | 5003       | Non-small-cell lung cancer          | 36          | M      | Y   | n                   | CCDC6-RET fusion           | Lenvatinib            | Off-label use       |
| 19  | 5077       | Histiocytic sarcoma                 | 18          | M      | Y   | Y                   | MAP2K1 mutation             | Trametinib            | Off-label use       |
| 20  | 5098       | Non-small-cell lung cancer          | 46          | M      | n   | n                   | EML4-ALK fusion            | Alectinib            | Approved drug       |
| 21  | 5041       | Non-small-cell lung cancer          | 51          | F      | n   | n                   | EGFR mutation (p.V769_D770insGQR) | Afatinib           | Approved drug       |
| 22  | 5162       | Non-small-cell lung cancer          | 54          | F      | n   | n                   | EGFR mutation (p.E746_T751delinsL) | Afatinib           | Approved drug       |
| 23  | 5091       | Non-small-cell lung cancer          | 64          | F      | n   | n                   | EGFR mutation (p.S752_L759del) | Gefitinib           | Approved drug       |
| 24  | 5115       | Non-small-cell lung cancer          | 35          | M      | Y   | n                   | CD74-ROS1 fusion            | Crizotinib           | Approved drug       |
| 25  | 5071       | Melanoma                            | 60          | M      | n   | Y                   | Tumor mutation burden high  | Nivolumab            | Approved drug       |

ADC, antibody-drug conjugate; AYA, adolescent and young adult (15-39 years); F, female; FGFR, fibroblast growth factor receptor; HDM2, human double minute 2 homolog; HER2, human epidermal growth factor receptor 2; M, male; TOP-GEAR, Trial of Onco-Panel for Gene-profiling to Estimate both Adverse events and Response during cancer treatment; TORC1/2, target of rapamycin complex 1/2; Y, yes; n, no.
dedifferentiated liposarcomas showed amplification of MDM2, a biomarker (evidence level 2) for diagnosis of this tumor type. Therefore, these results supported pathological diagnosis of these tumors. In addition, a hotspot IDH1 mutation (R132H) was detected in 2 glioma cases. This is a biomarker (evidence level 2) for predicting a good prognosis.

### 4 | Discussion

Here, we present the results of a prospective study designed to analyze 114 cancer-related genes using the NCC Oncopanel test. The test, including bioinformatics analysis, was carried out in a quality-assured laboratory at NCCH. Among the 230 analyzed cases, gene profiling data were obtained for 187 (81.3%). Corresponding peripheral blood DNAs were used to accurately address somatic and germline mutations, as well as TMBs. The 187 samples comprised surgical or biopsy FFPE specimens used in daily clinics and covered more than 30 cancer types, including rare cancers. Approximately half of the specimens (n = 112, 48.7%) were obtained from hospitals in Japan other than NCCH. The success rate was similar to that reported for other gene panel tests undertaken at CLIA-assured laboratories (80%-85%) in the USA.

At least 1 genetic aberration was detected in 83.4% of analyzed cases, and 59.4% had actionable gene aberrations, including a high TMB. This result is also comparable with those reported by prospective studies in the USA that used different gene panel tests; these tests detected actionable gene aberrations in approximately half of cases examined (40%-60%). Thus, we conclude that the NCC Oncopanel test is feasible in the clinical setting in Japan. Reasons for test failure included DNA of low quality/quantity and tissue cross-contamination. Tissue cross-contamination was detected in 3.9% of the study samples; this was a major pre-analytical issue as recently discussed. This rate of our study is consistent with a recent report indicating that 3% of cases showed clinically significant (ie, more than 5%) levels of cross-contamination during routine clinical sequencing. In our study, most of the cross-contaminated tissue samples yielded poor quality and/or low yields of DNA (Table S5). Some tumor samples with poor-quality DNA also failed due to low read depth. In fact, DNAs from tumor samples stored for long periods (more than 3 years) often yielded poor-quality DNA; therefore, selecting tumor specimens appropriate for NGS (ie, fresh and large samples) as well as careful laboratory processing is critical for accurate and robust analysis using the NCC Oncopanel test.

The percentage of carcinoma cases with actionable gene aberrations related to drug selection was greater (65.5%) than that of sarcoma cases (33.3%). These percentages for all types of tumor will be increased in future by developing drugs that target currently "undruggable" alterations, such as deleterious mutations in SWI/SNF chromatin regulator genes, which are detected in tumors such as sarcoma. In addition, we classified several detected mutations in currently druggable genes as "variants of unknown significance" due to lack of biological and clinical evidence. Annotation of those variants of unknown significance will also increase the percentage of patients with detected gene aberrations linked to molecular-targeted therapy.
Aside from identifying druggable gene aberrations, the gene panel test proved useful for diagnosis (6 hereditary tumors and 2 liposarcomas) and prognosis (2 gliomas). Detection of germline mutations in cancer predisposing genes provides doctors with valuable information about hereditary cancers. Detection of typical gene aberrations in a few cases facilitated diagnosis or prognosis assessment by treating physicians.

The NCC Oncopanel test led to drug treatment according to actionable gene aberrations in 25 cases (13.4%). These included 7 cases of adolescent and young adult (aged 15-39 years) and rare cancers (Table 2). The prognosis for adolescent and young adult and rare cancers has improved more slowly than that for other groups; therefore, efficient therapeutic regimens for these cancers are needed urgently.43 Drug treatment according to gene panel test results will facilitate development of drugs by promoting drug repositioning and clinical trials. Unfortunately, at present, identification of actionable gene aberrations related to drug selection does not mean that the patient receives treatment with a therapeutic agent specific for his/her aberration. Indeed, there was a large difference between the percentage of patients with actionable gene aberrations (59.4%) and the percentage that received therapy with a drug targeting that aberration (13.4%). Unfortunately, there were no available/accessible genomically matched clinical trials or drugs for the majority of patients with actionable gene aberrations. A recent prospective cohort study in the USA revealed that only 11% of patients receiving the MSK-IMPACT gene panel test were subsequently enrolled on genomically matched clinical trials.3 The gaps between the number of patients with actionable mutations and those receiving genomically matched therapy indicate the need to develop drugs targeting new genes covering not only druggable kinase genes but also nonkinase genes such as epigenomic and transcriptional regulator genes, which are often mutated in a variety of tumors.1,44 Developing drugs that target such currently undruggable molecules will be of great help.

The NCC Oncopanel test has recently been approved by the PMDA in the SAKIGAKE program of the MHLW45 (OncoGuide NCC Oncopanel System) and will be reimbursed by the national insurance system. After implementation, several challenges will remain. First, the amount of cancer genomic data increases daily; therefore, the significance of gene aberrations with respect to therapy, diagnosis, and prognosis requires continuous re-evaluation. Clinical oncologists and molecular tumor board members must keep up-to-date with information about actionable gene aberrations and investigational drugs. The cancer knowledge database being established by the Center for Cancer Genomics and Advanced Therapeutics at the NCC, Japan, will be a great help (https://www.ncc.go.jp/en/information/2018/0601/index.html). Second, the NCC Oncopanel test analyzes both tumor and nontumor DNA; therefore, germ-line mutations will be identified. Germline mutations responsible for hereditary disease are present in a small percentage of East Asians.46 Therefore, appropriate annotation of germline mutations and subsequent genetic counseling, coupled with a total care package, must be undertaken by each hospital. Routine performance of gene panel tests will improve patient experiences in oncology clinics and promote drug development.

ACKNOWLEDGMENTS
This work was supported in part by grants-in-aid from the Japan Agency for Medical Research and Development (AMED) (JP18kk0205004 and JP18kk1403003), and the National Cancer Center Research and Development Fund (27-A-1, 30-A-6, and NCC Biobank). The authors are grateful to Shunsuke Kondo, Shigehisa Kitano, Fumihiko Nakatani, Makoto Ohno, Koji Izutsu, Ayumu Arakawa, Kenjiro Namikawa, Aiko Maejima, Tomoyasu Kato, Seichi Yoshimoto, Chiemi Kojima, Kimihiko Kawamura, Yasuo Shibuki, Kazuya Tokita, Mizuki Takatsu, Tadashi Kumamoto, Keiko Wakakuwa, Yuki Murai, Taro Shibata, and Aya Kuchiba (and to other physicians and staff at the National Cancer Center and other hospitals), who contributed to the TOP-GEAR project. We also thank staff at Riken Genesis, Sysmex, and Mitsui Knowledge Industry.

CONFLICT OF INTEREST
K.S., T.K., and A.O. are recipients of a collaborative research grant from the Sysmex Corporation. The other authors have no conflicts of interest to declare.

ORCID

Yutaka Fujiwara https://orcid.org/0000-0001-6981-0800
Akihiro Shimomura https://orcid.org/0000-0002-2557-8170
Takafumi Koyama https://orcid.org/0000-0001-5807-8458
Noriko Motoi https://orcid.org/0000-0001-7098-3311
Akiko Maeshima https://orcid.org/0000-0001-7251-7920
Nobuyoshi Hirooka https://orcid.org/0000-0003-4215-4385
Kenji Tamura https://orcid.org/0000-0002-3514-9927
Takashi Kohno https://orcid.org/0000-0002-5371-706X

REFERENCES

1. Kohno T. Implementation of “clinical sequencing” in cancer genome medicine in Japan. Cancer Sci. 2018;109:507-512.
2. Kou T, Kanai M, Yamamoto Y, et al. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci. 2017;108:1440-1446.
3. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703-713.
4. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.
5. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.
6. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
7. Chakradhar S. Tumor sequencing takes off, but insurance reimbursement lags. Nat Med. 2014;20:1220-1221.
8. Fujiwara Y. Evolution of frameworks for expediting access to new drugs in Japan. Nat Rev Drug Discovery. 2016;15:293-294.
9. Sunami K, Takahashi H, Tsuchihara K, et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0). Cancer Sci. 2018;109:2980-2985.
10. Tanabe Y, Ichikawa H, Kohno T, et al. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer. 2016;15:73.
11. Fujiwara Y, Yonemori K, Shibata T, Okita N, Ushirozawa N. Japanese universal health care faces a crisis in cancer treatment. Lancet Oncol. 2015;16:251-252.
12. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754-1760.
13. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589-595.
14. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMNet Journal. 2011;17:10-12.
15. Kato M, Nakamura H, Nagai M, et al. A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. Genome Med. 2018;10:44.
16. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24-26.
17. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945-D950.
18. Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics. 2011;27:2601-2602.
19. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:249-255.
20. McKenn A, Hann M, Bank E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-1303.
21. Yamaguchi-Kabata Y, Nariai N, Kawai Y, et al. iJGVD: an integrative Japanese genome variation database based on whole-genome sequencing. Hum Genome Var. 2015;2:15050.
22. Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4-23.
23. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062-d7.
24. Kanke Y, Shimomura A, Saito M, et al. Gene aberration profile of tumors of adolescent and young adult females. Oncotarget. 2018:9:6288-6237.
25. Saito M, Shimada Y, Shiraishi K, et al. Development of lung adenocarcinomas with exclusive dependence on oncogene fusion. Can Res. 2015;75:2264-2271.
26. Honda T, Sakashita H, Masai K, et al. Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia. JCO Precis Oncol. 2018;2:1-24.
27. Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521-528.
28. Soh SX, Siddiqui FJ, Allen JC, et al. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017;8:41474-41486.
29. Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107:713-720.
30. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003-1010.
31. Nik-Zainal S, Davies H, Stahl J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47-54.
32. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378:2093-2104.
33. Grobner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321-327.
34. Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042-1056.
35. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189-193.
36. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:413-419.
37. Freamont GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
38. Hovelson DH, McDaniel AS, Cani AK, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015;17:385-399.
39. Sehn JK, Spencer DH, Pfeijter JD, et al. Occult specimen contamination in routine clinical next-generation sequencing testing. Am J Clin Pathol. 2015;144:667-674.
40. St Pierre R, Kadoch C. Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Curr Opin Genet Dev. 2017;42:56-67.
41. Lasko LM, Jakob CG, Edalji RP, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. 2017:550:128-132.
42. Ogiwara H, Sasaki M, Mitachi T, et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 2016;6:430-445.
43. Schmidt C. Lack of progress in teen and young adult cancers concerns researchers, prompts study. J Natl Cancer Inst. 2006;98:1760-1763.
44. Ogiwara H, Takahashi K, Sasaki M, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell. 2019;35:177-190.
45. Oye KA, Eichler HG, Hoos A, Mori Y, Mullin TM, Pearson M. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan. Clin Pharmacol Ther. 2016;100:626-632.
46. Tang CS, Dattani S, So MT, et al. Actionable secondary findings from whole-genome sequencing of 954 East Asians. Hum Genet. 2018;137:31-37.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019;110:1480–1490. [https://doi.org/10.1111/cas.13969](https://doi.org/10.1111/cas.13969)